
# Advanced Nanocarrier-Mediated Pharmaceutical Systems: Mechanistic Insights into Controlled, Targeted, and Sustained Drug Release for Contemporary Therapeutic Applications

**Dr Rafael S Sato [1*] , Dr Sophie Caron [2] , Dr Thiago P. Lewis [3] , Dr Sophie Caron [4]**
[1-2] Department of Agricultural Engineering, Tamil Nadu Agricultural University, Coimbatore, India
[3] Department of Agri-Robotics and Automation, Technical University of Munich, Munich, Germany
[4] Department of Agricultural Engineering, University of Alberta, Edmonton, Canada

* Corresponding Author: **Dr Rafael S Sato**

## Article Info

**P-ISSN:** 3051-3421
**E-ISSN:** 3051-343X
**Volume:** 04
**Issue:** 01
**Received:** 02-01-2023
**Accepted:** 03-02-2023
**Published:** 05-03-2023
**Page No:** 17-24

**Abstract**
Pharmaceutical nanotechnology has revolutionized drug delivery by enabling precise control over drug release kinetics, biodistribution, and therapeutic outcomes. Conventional drug formulations often suffer from poor bioavailability, non-specific distribution, rapid clearance, and systemic toxicity, necessitating the development of advanced nanocarrier systems. This review examines emerging trends in pharmaceutical nanotechnology focused on controlled, targeted, and sustained drug release applications. Key nanocarrier platforms including polymeric nanoparticles, liposomes, solid lipid nanoparticles, dendrimers, micelles, and inorganic nanocarriers are critically evaluated for their physicochemical properties, drug loading mechanisms, and release kinetics. The mechanistic principles governing controlled drug release—including diffusion-mediated, erosion-controlled, and stimuli-responsive mechanisms—are systematically analyzed alongside passive and active targeting strategies that exploit enhanced permeability and retention effects, ligand-receptor interactions, and environmental triggers. Therapeutic applications in oncology, infectious diseases, chronic inflammatory conditions, and neurological disorders demonstrate the translational potential of these systems. Despite significant advances, formulation complexity, scalability challenges, regulatory uncertainties, and immunological concerns remain critical barriers to clinical translation. Future developments in personalized nanomedicine, artificial intelligence-guided design, and regulatory harmonization are expected to accelerate the clinical adoption of pharmaceutical nanotechnology. This comprehensive review provides pharmaceutical scientists and clinicians with mechanistic understanding and practical insights into the design, optimization, and therapeutic implementation of next-generation nanocarrier-based drug delivery systems.

**Keywords:** Pharmaceutical nanotechnology; Controlled drug release; Targeted drug delivery; Sustained release systems; Nanocarriers; Nanomedicine

## 1. Introduction

The pharmaceutical industry faces persistent challenges in achieving optimal therapeutic outcomes due to limitations inherent in conventional drug formulations. Many potent therapeutic agents exhibit poor aqueous solubility, limited membrane permeability, rapid metabolic degradation, and non-selective tissue distribution, resulting in suboptimal bioavailability and significant off-target toxicity [1, 2]. These pharmacokinetic and pharmacodynamic limitations necessitate frequent dosing regimens, reduce patient compliance, and often lead to therapeutic failure. Pharmaceutical nanotechnology has emerged as a transformative approach to overcome these fundamental challenges by engineering drug delivery systems at the nanoscale,

typically ranging from 1 to 1000 nanometers [3, 4].

Nanocarrier-based drug delivery systems offer unprecedented control over drug release profiles, enabling sustained therapeutic concentrations, minimizing dosing frequency, and reducing systemic adverse effects [5, 6]. The ability to engineer surface properties, control particle size distribution, and incorporate targeting ligands facilitates selective accumulation at diseased tissues while sparing healthy organs [7]. Furthermore, nanocarriers can protect encapsulated drugs from premature degradation, enhance cellular uptake through endocytic pathways, and enable intracellular delivery of therapeutics that cannot otherwise cross biological membranes [8].

Controlled drug release refers to the precise temporal regulation of drug liberation from nanocarrier matrices, achieved through manipulation of formulation parameters and material properties [9]. Targeted drug delivery exploits pathophysiological characteristics of diseased tissues or employs molecular recognition strategies to achieve site-specific drug accumulation [10]. Sustained drug release maintains therapeutic drug concentrations over extended periods, reducing the need for frequent administration while maintaining efficacy [11]. The integration of these three principles represents the cornerstone of contemporary pharmaceutical nanotechnology.

This review systematically examines emerging trends in pharmaceutical nanotechnology with specific emphasis on controlled, targeted, and sustained drug release applications. The article critically evaluates major nanocarrier platforms, elucidates the mechanistic principles governing drug release and targeting, analyzes therapeutic applications across multiple disease areas, and discusses translational challenges and future directions. The scope is deliberately focused on pharmaceutical applications, excluding non-medical nanotechnology domains, to provide pharmaceutical scientists and clinicians with actionable insights for rational nanocarrier design and clinical implementation.

## 2. Nanocarrier-Based Drug Delivery Systems

### 2.1. Polymeric Nanoparticles

Polymeric nanoparticles represent one of the most versatile nanocarrier platforms, fabricated from biodegradable or non-biodegradable polymers that can be tailored to achieve specific drug release profiles [12]. Poly(lactic-co-glycolic acid) (PLGA) remains the most extensively studied biodegradable polymer due to its FDA-approved status, tunable degradation kinetics, and excellent biocompatibility [13]. PLGA nanoparticles undergo hydrolytic degradation, releasing encapsulated drugs in a controlled manner that can be modulated by altering the lactide-to-glycolide ratio, molecular weight, and crystallinity [14]. Polycaprolactone (PCL), polyethylene glycol (PEG), and chitosan represent alternative polymeric materials offering distinct advantages including prolonged circulation times, mucoadhesive properties, and pH-responsive behavior [15, 16].

Drug loading in polymeric nanoparticles occurs through encapsulation during particle formation or post-loading via absorption, with loading efficiency influenced by drug-polymer interactions, hydrophobicity, and formulation method [17]. Nanoprecipitation, emulsification-solvent evaporation, and microfluidic techniques enable precise control over particle size, morphology, and drug distribution within the polymeric matrix [18]. The drug release mechanism from polymeric nanoparticles typically involves initial burst release from surface-associated drug molecules, followed by sustained release governed by polymer degradation and drug diffusion through the polymeric network [19].

### 2.2. Lipid-Based Nanocarriers

Lipid-based nanocarriers encompass liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid-polymer hybrid systems, offering exceptional biocompatibility and versatile drug encapsulation capabilities [20]. Liposomes consist of phospholipid bilayers that spontaneously assemble in aqueous environments, creating hydrophilic cores for water-soluble drugs and hydrophobic bilayers for lipophilic compounds [21]. Surface modification with PEG (PEGylation) significantly extends circulation half-life by reducing opsonization and reticuloendothelial system clearance, enabling passive tumor accumulation through enhanced permeability and retention (EPR) effects [22].

Solid lipid nanoparticles address the physical instability of conventional liposomes by replacing liquid lipids with solid lipids at physiological temperatures, providing controlled drug release through lipid matrix erosion and drug diffusion [23]. Nanostructured lipid carriers incorporate liquid lipids into solid lipid matrices, creating imperfect crystalline structures with enhanced drug loading capacity and reduced drug expulsion during storage [24]. The drug release kinetics from lipid nanocarriers can be precisely controlled by manipulating lipid composition, crystallinity, and particle size distribution [25].

### 2.3. Emerging Nanocarrier Platforms

Dendrimers are highly branched, monodisperse macromolecules with well-defined three-dimensional architectures featuring numerous surface functional groups amenable to drug conjugation and targeting ligand attachment [26]. The internal cavities of dendrimers provide drug encapsulation sites, while surface groups enable multivalent interactions with biological targets [27]. Polymeric micelles self-assemble from amphiphilic block copolymers in aqueous media, forming core-shell structures with hydrophobic cores for drug solubilization and hydrophilic shells for colloidal stability [28].

Inorganic nanocarriers including gold nanoparticles, mesoporous silica nanoparticles, and carbon nanotubes offer unique physicochemical properties such as high surface area, tunable porosity, and potential for multimodal imaging and therapy [29]. Mesoporous silica nanoparticles possess ordered pore structures enabling high drug loading, surface functionalization with targeting ligands, and stimuli-responsive drug release through pore capping strategies [30].

## 3. Mechanisms of Controlled, Targeted, and Sustained Drug Release

### 3.1. Controlled Release Kinetics

Controlled drug release from nanocarriers occurs through diffusion-mediated, erosion-controlled, osmotic, or stimuli-responsive mechanisms [31]. Diffusion-mediated release follows Fickian kinetics where drug molecules traverse the nanocarrier matrix or membrane according to concentration gradients, with release rates governed by drug solubility, diffusion coefficient, and matrix porosity [32]. Erosion-controlled release involves gradual degradation of the nanocarrier material, with drug liberation coupled to polymer hydrolysis or enzymatic degradation [33]. The mathematical

modeling of release kinetics using zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Hixson-Crowell models enables prediction of *in vivo* performance and rational formulation optimization [34].

Stimuli-responsive nanocarriers respond to endogenous or exogenous triggers including pH, temperature, enzymes, redox gradients, light, and magnetic fields, enabling spatiotemporal control over drug release [35]. pH-responsive systems exploit the acidic microenvironments characteristic of tumors, endosomes, and inflammatory sites by incorporating acid-labile linkages or pH-sensitive polymers that undergo conformational changes triggering drug release [36]. Thermoresponsive polymers exhibit lower critical solution temperatures enabling temperature-triggered drug release, particularly useful in combination with localized hyperthermia [37].

### 3.2. Targeting Strategies

Passive targeting exploits pathophysiological characteristics of diseased tissues, most notably the enhanced permeability and retention effect observed in solid tumors [38]. Tumor vasculature exhibits increased permeability due to incomplete endothelial cell junctions and defective lymphatic drainage, facilitating extravasation and accumulation of nanocarriers sized between 10-200 nanometers [39]. Nanocarrier size, surface charge, and hydrophilicity critically influence biodistribution, circulation time, and passive accumulation efficiency [40].

Active targeting employs molecular recognition strategies by decorating nanocarrier surfaces with targeting ligands that specifically bind to receptors overexpressed on target cells [41]. Antibodies, antibody fragments, peptides, aptamers, and small molecules serve as targeting moieties that enhance cellular uptake through receptor-mediated endocytosis [42]. Folate receptors, transferrin receptors, epidermal growth factor receptors, and integrins represent extensively studied targets for active delivery to cancer cells [43]. The ligand density, orientation, and affinity significantly impact targeting efficiency and cellular internalization [44].

### 3.3. Sustained Drug Delivery Approaches

Sustained drug delivery maintains therapeutic concentrations over extended periods through controlled release formulations, reducing dosing frequency and improving patient compliance [45]. The design of sustained-release nanocarriers requires careful consideration of drug pharmacokinetics, therapeutic window, and target tissue characteristics [46]. Zero-order release kinetics represents the ideal sustained release profile, maintaining constant drug concentrations within the therapeutic window while minimizing fluctuations that cause toxicity or subtherapeutic effects [47].

## 4. Therapeutic Applications

### 4.1. Cancer Therapy

Oncological applications represent the most extensively developed area of pharmaceutical nanotechnology, with multiple nanoformulations achieving clinical approval including Doxil (PEGylated liposomal doxorubicin), Abraxane (albumin-bound paclitaxel), and Onivyde (liposomal irinotecan) [48]. Nanocarrier-mediated delivery addresses the dose-limiting toxicities of conventional chemotherapy by altering drug biodistribution, reducing cardiotoxicity, nephrotoxicity, and myelosuppression [49]. The EPR effect facilitates passive tumor accumulation, while active targeting with antibodies against HER2, EGFR, or folate receptors enhances intratumoral drug concentrations [50].

Combination nanotherapies co-encapsulating multiple drugs with distinct mechanisms of action demonstrate synergistic efficacy and overcome multidrug resistance. Stimuli-responsive nanocarriers triggered by tumor microenvironment acidity or hypoxia enable selective intratumoral drug release while minimizing systemic exposure. Theranostic nanocarriers integrating diagnostic imaging and therapeutic capabilities facilitate real-time monitoring of treatment response and personalized dose optimization.

### 4.2. Infectious and Chronic Diseases

Antimicrobial nanocarriers address the escalating crisis of antibiotic resistance by enhancing drug penetration into bacterial biofilms, enabling intracellular delivery for eradication of intracellular pathogens, and facilitating sustained drug release at infection sites. Liposomal amphotericin B (AmBisome) demonstrates superior safety profiles compared to conventional formulations for treatment of systemic fungal infections. Tuberculosis treatment benefits from nanocarrier-mediated delivery of rifampicin and isoniazid, enabling reduced dosing frequency and improved patient compliance.

Chronic inflammatory diseases including rheumatoid arthritis benefit from nanocarrier-mediated delivery of corticosteroids and disease-modifying antirheumatic drugs to inflamed joints, exploiting enhanced vascular permeability at inflammatory sites. Neurological disorders represent challenging targets due to blood-brain barrier impermeability, addressed through surface modification with transferrin, lactoferrin, or cell-penetrating peptides that facilitate transcytosis. Nanocarrier-mediated delivery of insulin via oral or pulmonary routes aims to replace subcutaneous injections for diabetes management.

## 5. Challenges and Future Perspectives

### 5.1. Formulation and Stability Challenges

Pharmaceutical development of nanocarrier systems faces significant formulation challenges including maintaining colloidal stability during storage, preventing drug leakage, achieving reproducible particle size distributions, and ensuring scalable manufacturing processes. Lyophilization with appropriate cryoprotectants improves long-term storage stability but may cause particle aggregation or structural alterations. Sterilization methods compatible with thermolabile nanoformulations require careful validation to ensure product sterility without compromising physicochemical properties.

### 5.2. Scale-Up, Regulatory, and Clinical Translation Barriers

Translation from laboratory-scale synthesis to large-scale manufacturing presents substantial challenges related to batch-to-batch reproducibility, process validation, and quality control. Regulatory frameworks for nanomedicines remain evolving, with requirements for extensive physicochemical characterization, toxicological evaluation, and demonstration of clinical benefit over existing therapies. The complexity of nanocarrier formulations necessitates comprehensive quality-by-design approaches incorporating

critical quality attributes and process analytical technology. Immunological concerns including complement activation, hypersensitivity reactions, and accelerated blood clearance following repeated dosing pose significant safety considerations requiring thorough preclinical evaluation. The lack of standardized characterization methods and insufficient understanding of nanocarrier-biological interactions complicate regulatory approval and clinical adoption.

### 5.3. Future Research Directions

Future developments in pharmaceutical nanotechnology will emphasize personalized nanomedicine approaches utilizing patient-specific biomarkers to guide nanocarrier design and treatment selection. Artificial intelligence and machine learning algorithms will accelerate nanocarrier optimization by predicting formulation performance from physicochemical parameters. Biomimetic nanocarriers incorporating cell membranes or exosomes promise enhanced biocompatibility and natural targeting capabilities. Combination immunotherapy with checkpoint inhibitors and nanocarrier-delivered chemotherapy demonstrates synergistic antitumor efficacy warranting clinical investigation

## 6. Figure




**Fig 1:** Overview of pharmaceutical nanocarriers for controlled, targeted, and sustained drug delivery




**Fig 2 :** Mechanisms governing controlled and sustained drug release from nanocarrier systems




**Fig 3:** Targeting strategies in pharmaceutical nanotechnology (passive, active, and stimuli-responsive targeting)

## 7. Tables

**Table 1:** Major nanocarrier systems and their pharmaceutical applications+

| Nanocarrier Type | Size Range (nm) | Drug Loading Mechanism | Representative Applications | Clinical Examples |
|---|---|---|---|---|
| Polymeric nanoparticles (PLGA) | 50-300 | Encapsulation, conjugation | Cancer, vaccines, gene delivery | Not yet approved |
| Liposomes | 50-400 | Bilayer incorporation, aqueous core encapsulation | Cancer, fungal infections, vaccines | Doxil, AmBisome, Onivyde |
| Solid lipid nanoparticles | 50-1000 | Lipid matrix incorporation | Oral delivery, cosmetics, parenteral | Not yet approved |
| Dendrimers | 5-20 | Internal cavity encapsulation, surface conjugation | Cancer, gene delivery, imaging | Under investigation |
| Polymeric micelles | 10-100 | Hydrophobic core solubilization | Cancer, anti-inflammatories | Genexol-PM |
| Mesoporous silica | 50-300 | Pore encapsulation, surface adsorption | Controlled release, imaging | Under investigation |
| Gold nanoparticles | 10-150 | Surface conjugation, photothermal | Cancer therapy, diagnostics | CYT-6091 (Phase I) |

**Table 2:** Physicochemical properties of nanocarriers influencing drug loading and release behavior

| Property | Impact on Drug Loading | Impact on Release Kinetics | Impact on Biodistribution |
|---|---|---|---|
| Particle size | Higher surface area increases loading capacity; size determines loading method | Smaller particles exhibit faster release due to higher surface-to-volume ratio | Size 10-200 nm optimal for EPR; <5 nm renal clearance; >200 nm splenic filtration |
| Surface charge | Electrostatic interactions enhance ionic drug loading | Charged surfaces accelerate release in physiological media | Neutral/slightly negative charges reduce opsonization and prolong circulation |
| Hydrophobicity | Determines affinity for lipophilic vs hydrophilic drugs | Hydrophobic matrices provide sustained release; hydrophilic enable faster release | Hydrophobic surfaces promote protein adsorption and RES uptake |
| Crystallinity | Ordered structures reduce loading capacity | Crystalline regions slow diffusion-mediated release | Influences particle stability and degradation rate *in vivo* |
| Porosity | High porosity increases drug loading capacity | Porous structures enable diffusion-controlled release | May increase particle fragility and premature drug leakage |
| Polymer molecular weight | Higher MW enables greater drug incorporation | Higher MW prolongs degradation and extends release duration | Influences circulation time and biodegradation rate |

**Table 3:** Therapeutic applications of nanotechnology-based drug delivery systems

| Disease Area | Nanocarrier Type | Drug/Therapeutic Agent | Targeting Strategy | Clinical Status/Outcome |
|---|---|---|---|---|
| Breast cancer | PEGylated liposomes | Doxorubicin | Passive (EPR effect) | FDA approved (Doxil) |
| Pancreatic cancer | Liposomes | Irinotecan | Passive targeting | FDA approved (Onivyde) |
| Ovarian cancer | Albumin nanoparticles | Paclitaxel | Passive accumulation | FDA approved (Abraxane) |
| Lung cancer | Polymeric micelles | Paclitaxel | Passive targeting | Approved in Korea (Genexol-PM) |
| Systemic fungal infections | Liposomes | Amphotericin B | Organ distribution | FDA approved (AmBisome) |
| Tuberculosis | PLGA nanoparticles | Rifampicin, isoniazid | Macrophage targeting | Preclinical/clinical trials |
| Rheumatoid arthritis | Liposomes | Methotrexate, corticosteroids | Inflammation-mediated accumulation | Clinical trials |
| Brain tumors | Polymeric nanoparticles | Temozolomide, doxorubicin | Active targeting (transferrin) | Clinical trials |
| Diabetes | Polymeric nanoparticles | Insulin | Oral/pulmonary delivery | Clinical development |

**Table 4:** Advantages, limitations, and translational challenges of pharmaceutical nanocarriers

| Aspect | Advantages | Limitations | Translational Challenges |
|---|---|---|---|
| Drug delivery efficiency | Enhanced bioavailability; protection from degradation; controlled release kinetics | Complex formulation requirements; potential drug leakage during storage | Demonstrating superior efficacy over conventional formulations in clinical trials |
| Targeting capability | Passive EPR-mediated accumulation; active ligand-receptor targeting; stimuli-responsive release | EPR variability between patients; limited tumor penetration; targeting ligand immunogenicity | Inter-patient heterogeneity in EPR effect; developing companion diagnostics |
| Manufacturing | Versatile platforms; tunable properties; multiple administration routes | Batch-to-batch variability; scale-up difficulties; sterilization challenges | Establishing GMP manufacturing; ensuring reproducibility; cost-effectiveness |
| Safety profile | Reduced systemic toxicity; improved therapeutic index | Potential immunogenicity; complement activation; accumulation in RES organs | Long-term toxicity studies; understanding accelerated blood clearance phenomenon |
| Regulatory approval | Precedent with approved nanomedicines; established characterization methods | Complex characterization requirements; lack of standardized methods; evolving guidelines | Meeting regulatory expectations; demonstrating clinical benefit; navigating approval pathways |
| Clinical translation | Multiple clinical trials ongoing; growing evidence base | High development costs; long timelines; need for specialized expertise | Securing funding; managing intellectual property; establishing clinical partnerships |

## 8. Conclusion

Pharmaceutical nanotechnology has fundamentally transformed drug delivery by enabling unprecedented control over drug release kinetics, biodistribution, and therapeutic targeting. Advanced nanocarrier systems including polymeric nanoparticles, lipid-based carriers, dendrimers, micelles, and inorganic nanoplatforms provide versatile platforms for controlled, targeted, and sustained drug delivery across diverse therapeutic applications. The integration of passive and active targeting strategies with stimuli-responsive release mechanisms maximizes therapeutic efficacy while minimizing systemic toxicity. Despite remarkable progress evidenced by multiple clinically approved nanoformulations, significant challenges related to scalable manufacturing, regulatory harmonization, immunological safety, and clinical translation persist. Future advances in personalized nanomedicine, artificial intelligence-guided design, and regulatory standardization will accelerate the clinical adoption of pharmaceutical nanotechnology, ultimately improving patient outcomes across oncology, infectious diseases, chronic inflammatory conditions, and beyond. Continued interdisciplinary collaboration among pharmaceutical scientists, clinicians, regulatory agencies, and industry partners remains essential to fully realize the transformative potential of nanocarrier-mediated drug delivery systems.

## 9. References


1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
2. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42(12):742-55.
3. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
4. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
5. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-22.
6. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24.
7. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-51.
8. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182-95.
9. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2010;1:149-73.
10. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.
11. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-3.
12. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
13. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-97.
14. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems. Int J Pharm. 2011;415(1-2):34-52.
15. Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release. 2016;238:176-85.
16. Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. J Control Release. 2015;206:161-76.
17. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug

Deliv Rev. 2003;55(3):329-47.
18. Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, *et al*. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008;8(9):2906-12.
19. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(5):5-24.
20. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
21. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
22. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28-51.
23. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery. Eur J Pharm Biopharm. 2000;50(1):161-77.
24. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143-61.
25. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161-72.
26. Tomalia DA, Naylor AM, Goddard WA 3rd. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl. 1990;29(2):138-75.
27. Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, *et al*. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9(1):247.
28. Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844-92.
29. Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30(2):1902634.
30. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41(7):2590-605.
31. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364(2):328-43.
32. Peppas NA, Narasimhan B. Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems. J Control Release. 2014;190:75-81.
33. Göpferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 1996;17(2):103-14.
34. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
35. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
36. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery. Biomaterials. 2016;85:152-67.
37. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev. 2006;58(15):1655-70.
38. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors. Adv Drug Deliv Rev. 2013;65(1):71-9.
39. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, *et al*. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
40. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-27.
41. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26.
42. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine. 2013;9(2):194-201.
43. Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14(3):203-19.
44. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481-503.
45. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-18.
46. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-63.
47. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121-36.
48. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143.
49. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-36.
50. Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769-84.